Hundreds of pharmacists are shifting from patient care roles to drug companies and specialty markets earning billions, according to Michael Hogue, PharmD, who said hospital pharmacies should counteract this trend.
An enzyme known as PI3K gamma may be able to reduce organ and tissue damage in patients who have COVID-19 or drug-resistant Staphylococcus aureus, researchers at the University of California San Diego found.
Eli Lilly's experimental Alzheimer's disease treatment, Kisunla — which slowed decline by up to 35% in clinical trials — has been approved by the FDA, after previously delaying its decision in March, the agency announced July 2.
A Mississippi federal judge has denied a request from Novartis Pharmaceuticals and the Pharmaceutical Research and Manufacturers of America for a preliminary injunction against state enforcement protecting 340B pricing for contract pharmacies.
The FTC has launched a probe into Teva Pharmaceuticals over contested drug patents the company refuses to remove from a federal registry, The Washington Post reported July 1.
Former FDA attorneys say the Supreme Court's recent decision to overturn Chevron deference, a decades-old legal precedent, could stall the development of new drugs and medical devices, Politico reported July 1.
If current trends continue, Michael Murphy, PharmD, said all payers will come to recognize pharmacists as healthcare providers by the end of the decade.
In the last year, the field of oncology has continued to grapple with significant challenges that have imposed formidable hurdles on cancer care worldwide.
